Cladribine is a purine nucleoside analog (PNA) synthesized by a simple substitution of a chlorine atom with a hydrogen atom at the position 2 of the purine ring of deoxyadenosine and resistant to deamination by adenosine deaminase (ADA) (Fig.
1).
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
References
Barete S, Lortholary O, Damaj G, et al. (2015) Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. pii: blood-2014-12-614743Google Scholar
Bryson H, Sorkin EM (1993) Cladribine. A review of its pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 46:872–894CrossRefPubMedGoogle Scholar
Freyer CW, Gupta N, Wetzler M, Wang ES (2015) Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? Am J Hematol 90:62–72Google Scholar
Pettitt AR (2003) Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br J Haematol 121:692–702CrossRefPubMedGoogle Scholar
Robak T (2001) Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 40:551–564CrossRefPubMedGoogle Scholar
Robak T, Lech-Marańda E, Korycka A (2006) Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 13:3165–3189CrossRefPubMedGoogle Scholar
Robak T, Robak P (2012) Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des 18:3373–88. http://www.ncbi.nlm.nih.gov/pubmed/20634380
Sigal DS, Miller HJ, Schram ED, Saven A (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 116:2884–96. http://www.ncbi.nlm.nih.gov/pubmed/20634380
